BRIEF published on 12/11/2025 at 07:05, 6 days 5 hours ago BioVersys lance un essai de phase 3 pour le BV100 et fait le point sur ses progrès commerciaux. Introduction En Bourse BioVersys Résistance Aux Médicaments BV100 Phase 3 Recherche Antibactérienne
BRIEF published on 12/11/2025 at 07:05, 6 days 5 hours ago BioVersys Initiates Phase 3 Trial for BV100 and Updates Business Progress IPO Drug Resistance BioVersys BV100 Phase 3 Antibacterial Research
PRESS RELEASE published on 12/11/2025 at 07:00, 6 days 5 hours ago BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update BioVersys AG initiates BV100 Phase 3 study for ventilator-associated bacterial pneumonia, achieving significant milestones in 2025 and upcoming key events in 2026 Clinical Trials Biopharmaceutical BioVersys AG BV100 Phase 3 Ventilator Associated Bacterial Pneumonia
BRIEF published on 11/10/2025 at 07:05, 1 month 7 days ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
BRIEF published on 11/10/2025 at 07:05, 1 month 7 days ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
PRESS RELEASE published on 11/10/2025 at 07:00, 1 month 7 days ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 1 month 11 days ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 1 month 11 days ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 1 month 11 days ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF published on 11/05/2025 at 07:05, 1 month 12 days ago BioVersys to Present at Stifel 2025 Annual Healthcare Conference New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
Published on 12/17/2025 at 11:37, 46 minutes ago Zentek Subsidiary Albany Graphite Corp. Achieves Near-Theoretical Anode Performance in Battery Suitability Independent Testing
Published on 12/17/2025 at 09:05, 3 hours 18 minutes ago Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
Published on 12/17/2025 at 08:00, 4 hours 23 minutes ago Pulsar Helium Awards Security Based Compensation
Published on 12/16/2025 at 23:20, 13 hours 3 minutes ago Tactical Resources Announces Shareholder Approval of Arrangement With Plum Acquisition Corp. III
Published on 12/16/2025 at 23:20, 13 hours 3 minutes ago GMV Minerals Announces Upsize of Non-Brokered Private Placement Pursuant to the Listed Issuer Financing Exemption
Published on 12/17/2025 at 11:12, 1 hour 11 minutes ago EQS-Adhoc: CEOTRONICS receives third SmG call-off worth approximately € 47 million
Published on 12/16/2025 at 21:45, 14 hours 38 minutes ago Mise à disposition du rapport financier annuel
Published on 12/16/2025 at 20:10, 16 hours 13 minutes ago donation of shares of Seval, member of the Feuillet family concert
Published on 12/16/2025 at 20:10, 16 hours 13 minutes ago Donation de titres de la société Seval, membre du concert familial Feuillet
Published on 12/16/2025 at 18:53, 17 hours 30 minutes ago Number of shares and voting rights - November 2025 (In French only)
Published on 12/16/2025 at 18:53, 17 hours 30 minutes ago Nombre total d'actions et droits de vote - novembre 2025
